CervoMed
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 8
- Market Cap
- $137.5M
- Introduction
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on ...
CervoMed presented neflamapimod's potential in treating DLB at CTAD, highlighting significant plasma GFAP reduction (p=0.015 vs placebo) in Phase 2a trials. The ongoing RewinD-LB Phase 2b study, with 80 patients per arm, aims for nearly 100% statistical power for primary endpoint, with topline results expected in December.
CervoMed Announces Key Takeaways from Oral Presentations at
Neflamapimod reduced plasma GFAP levels and improved clinical outcomes in DLB patients, with RewinD-LB Phase 2b trial enrolling DLB patients without tau pathology for optimized treatment effect evaluation.
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on ...
CervoMed to present neflamapimod data for dementia with Lewy bodies (DLB) at CTAD, indicating its potential as a treatment and the importance of the RewinD-LB Phase 2b study.
© Copyright 2025. All Rights Reserved by MedPath